EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis


New England Journal of Medicine 356(18): 1809-1822
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
BACKGROUND:A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.METHODS:In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes.RESULTS:Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P < 0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P < 0.001).CONCLUSIONS:A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures.


Accession: 013259105

PMID: 17476007

DOI: 10.1056/NEJMoa067312



Related references

Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acid. Patient Preference and Adherence 3: 189-193, 2009

Yearly zoledronic acid in postmenopausal osteoporosis. New England Journal of Medicine 357(7): 713; Author Reply 714-5, 2007

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis. Annals of PharmacoTherapy 42(7): 1085-1089, 2008

Low incidence of osteonecrosis of the jaw in postmenopausal women with osteoporosis taking zoledronic acid once yearly. Journal of Evidence-Based Dental Practice 9(1): 13-15, 2009

A once-yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis. Acp Journal Club 147(2): 31-31, 2007

Effect of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: Results from horizon-PFT. Annals of the Rheumatic Diseases 66(Suppl. 2): 101, 2007

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. Journal of Bone and Mineral Research 26(1): 12-18, 2011

Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: Results from horizon-PFT. 2007

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. Journal of the American Geriatrics Society 58(2): 292-299, 2010

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 24(9): 1544-1551, 2009